- EN
- JP
Metagen Therapeutics, Inc.
Bringing innovative medicine and pharmaceuticals to life
through cutting-edge microbiome science
News
-
【Press Release】Antibiotic Fecal Microbiota Transplantation for Ulcerative Colitis Patients Approved Under Japan’s Advanced Medical Care Program
January 4, 2023 JAPAN – Juntendo University (Bunkyo-ku, Tokyo, President: Hajime Arai) and Metagen Therapeutic […] -
【Press Release】 Metagen Therapeutics Raises 140M JPY in Pre-Series A For Its Microbiome Drug Discovery
10.06.2022 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yamagata […] -
【Press Release】Metagen Therapeutics and Juntendo University Establish a Joint Research Course, the ‘Microbiome Regeneration Course’
April 12, 2022 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yama […] -
【Press Release】Metagen Therapeutics, Inc. Joins Juntendo University In AMED’s ‘Project Focused on Developing Key Technology for Discovering and Manufacturing Drugs for Next-Generation Treatment and Diagnosis’ (Development of Next-Generation Drug Discovery Technology by Controlling Intestinal Microbiome)”
Promoting inflammatory bowel disease (IBD) seeds creation research with Juntendo University October 12, 2021 Y […] -
【Press Release】Metagen Therapeutics Raises Seed Round Funding of 90M JPY
March 17, 2021 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yama […]
Medical Services・Pipeline/Platform
The human microbiome is comprised of bacterial flora found throughout the human body, including in the intestines, skin, and oral cavity. Intestinal microbiome in particular, has a complex and dynamic population of microorganisms. In recent years, research on the intestinal flora has made significant progress and its symbiotic relationship with various diseases such as cancer, ulcerative colitis, Parkinson’s disease, and allergies, has become clear.
FMT and its research has been shown to be a safe and efficacious treatment around the world, and microbiome drug discovery is being actively carried out.
Founders

Chief Executive Officer
Taku Nakahara Ph.D., MBA

Chief Medical Officer
Dai Ishikawa MD, Ph.D.
Associate Professor
Juntendo University,
Department of Gastroenterology,
Faculty of Medicine


Chief Medical Officer
Shinji Fukuda MD, Ph.D.
Project Professor
Keio University,
Institute for Advanced Biosciences


Chief Technology Officer
Takuji Yamada Ph.D.
Associate Professor
Tokyo Institute of Technology,
School of Life Science and Technology

腸内細菌療法
メタジェンセラピューティクスはCMO石川が順天堂大学で研究してきた腸内細菌療法の普及を目指します。
Partners



Company
Metagen Therapeutics, Inc. (MGTx)
January 2020
Drug discovery and medical services using microbiome science
President & CEO Taku Nakahara
Director, CMO Dai Ishikawa
Director, CSO Jun Terauchi
Non-Executive Director Takashi Futami
Non-Executive Director Taira Kobayashi
Senior Scientific Advisor Shinji Fukuda
Senior Scientific Advisor Takuji Yamada
246-2 Mizukami, Kakuganji, Tsuruoka-city, Yamagata 997-0052 Japan
Toranomon Hills Business Tower 15F
1-17-1 Toranomon, Minato-ku, Tokyo 105-6415 Japan